AAT vs ABR

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a concerning lack of Altman Z-Score data, which raises transparency risks. Despite a high dividend yield of 7.51%, the payout ratio of 132.84% is unsustainable, supported by collapsing earnings—YoY EPS down 75% and revenue down 10.8%. Valuation metrics are mixed, with a Price/Book below 1 but a high Forward P/E of 24.97, while technical and analyst signals are uniformly bearish. The company has underperformed peers over 1Y, 3Y, and 5Y, with no insider buying and weak earnings consistency in recent quarters.

ABR exhibits weak financial health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score for definitive distress assessment. Despite a deep value appearance via a Price/Book of 0.64 and a Graham Number of $14.47—nearly double the current price of $7.74—the stock faces severe headwinds from declining revenue and earnings, high leverage, and an unsustainable dividend. Profitability margins are strong, but negative growth trends, a 184.81% payout ratio, and deteriorating fundamentals outweigh valuation appeal. Technical trend at 0/100 confirms strong bearish momentum.